Background: Exenatide (exendin-4) is an incretin mimetic currently marketed as an antidiabetic agent for patients with type 2 diabetes. In preclinical models, a reduction in body weight has also been shown in low-fat-fed, leptin receptor-deficient rodents. Objective: To more closely model the polygenic and environmental state of human obesity, we characterized the effect of exenatide on food intake and body weight in high-fat-fed, normal (those with an intact leptin signaling system) rodents. As glucagon-like peptide-1 receptor agonism has been found to elicit behaviors associated with visceral illness in rodents, we also examined the effect of peripheral exenatide on kaolin consumption and locomotor activity. Methods and results: High-fat-fed C57BL/6 mice and Sprague-Dawley rats were treated with exenatide (3, 10 and 30 mg/kg/ day) for 4 weeks via subcutaneously implanted osmotic pumps. Food intake and body weight were assessed weekly. At 4 weeks, body composition and plasma metabolic profiles were measured. Kaolin consumption and locomotor activity were measured in fasted Sprague-Dawley rats following a single intraperitoneal injection of exenatide (0.1-10 mg/kg). Exenatide treatment in mice and rats dose-dependently decreased food intake and body weight; significant reductions in body weight gain were observed throughout treatment at 10 and 30 mg/kg/day (Po0.05). Decreased body weight gain was associated with a significant decrease in fat mass (Po0.05) with sparing of lean tissue. Plasma cholesterol, triglycerides and insulin were also significantly reduced (Po0.05). Exenatide at 10 mg/kg significantly reduced food intake (Po0.05) but failed to induce kaolin intake. In general, locomotor activity was reduced at doses of exenatide that decreased food intake, although a slightly higher dose was required to produce significant changes in activity. Conclusion: Systemic exenatide reduces body weight gain in normal, high-fat-fed rodents, a model that parallels human genetic variation and food consumption patterns, and may play a role in metabolic pathways mediating food intake.
Introduction
Exenatide (exendin-4) is a 39-amino-acid peptide originally isolated from the salivary secretions of the Gila monster lizard (Heloderma suspectum). 1 It shares approximately 53%
homology with the mammalian incretin glucagon-like peptide-1 (GLP-1), and binds to and activates 2 the mammalian receptor for GLP-1 cloned from pancreatic b-cells. Exenatide is encoded by a gene that is distinct from the lizard ortholog of mammalian GLP-1. 4 Nonetheless, it shares many of the glucoregulatory actions observed with GLP-1 and is termed as 'incretin mimetic'. Unlike GLP-1, exenatide exhibits extended kinetics 5 due to resistance to proteolytic degradation by dipeptidyl peptidase IV (DPPIV), and has up to 3000-fold higher in vivo potency for glucose-lowering in some animal models. 6 Agents that activate the GLP-1 receptor possess high therapeutic potential for the treatment of diabetes; [7] [8] [9] exenatide is a currently marketed antidiabetic agent that is shown to improve glycemic control in patients with type 2 diabetes. [10] [11] [12] Glucose-lowering with exenatide, GLP-1 and GLP-1 analogs has been associated with several mechanisms of action, the first of which to be identified was an enhancement of glucose-dependent insulin secretion. 13, 14 The principal result of this insulinotropic effect is an acceleration of glucose disappearance into peripheral tissues. Exenatide additionally limits glucose appearance via glucose-dependent slowing of gastric emptying 15, 16 and suppression of inappropriately elevated postprandial glucagon secretion. [15] [16] [17] More recently, exenatide has been found to promote pancreatic b-cell proliferation and islet cell neogenesis in both animal and in vitro studies. 18, 19 In addition to its role in glycemic control, GLP-1 is a shortterm regulator of food intake, [20] [21] [22] an effect mediated via central GLP-1 receptors. 22, 23 Agents with actions similar to GLP-1, particularly those resistant to degradation by DPPIV, may be potential therapeutic agents in the treatment of obesity. 24 Exenatide reduces food intake in rodents following either central [25] [26] [27] or peripheral 18,27-31 administration, and repeated or chronic exposure reduces body weight. 6, 18, [26] [27] [28] Recent data from clinical trials have also revealed sustainable weight loss in exenatide-treated type 2 diabetic subjects. [10] [11] [12] In preclinical models, body weight reductions with systemic exenatide treatment have been demonstrated in leptinreceptor-deficient rodents under low-fat dietary conditions, 6, 18, 27, 28 and most report single-dose effects. One can readily postulate that polygenic models of obesity that mimic human consumption patterns may return a more physiologic picture of potential clinical utility. We therefore examined the potential of long-term exenatide treatment to dose-dependently reduce body weight in high-fat (HF)-fed, normal (those with an intact leptin signaling) mice and rats. Secondarily, one concern for a role of GLP-1 receptor agonism in satiety is potential activation of nonhomeostatic central nervous system (CNS) pathways, such as those mediating visceral illness, which could account for observed decreases in food intake. Central GLP-1 receptor activation in brain has been associated with preclinical measures of malaise such as conditioned taste aversion (CTA) 21, [32] [33] [34] and kaolin consumption. 34 Ingestion of kaolin (non-nutritive clay) in rodents is commonly used to determine the emetic properties of drugs and can be induced by a number of known emetic agents like the chemotherapeutic cisplatin. 35 We therefore examined the potential of exenatide to induce kaolin consumption in rats. As exenatide has also been shown to decrease locomotor activity, 31 we also examined exenatide's acute effect on general activity levels in rats. In both models, our goal was to discern doses at which food intake effects may be dissociated from potentially adverse actions of exenatide. Some of the data presented herein have appeared in abstract form.
36,37

Methods
All experiments were conducted in accordance with the protocols and guidelines approved by the Institutional Animal Care Committee and the NIH Guide to the Care and Use of Laboratory Animals. All animals were maintained on a 12 h light/dark cycle (housed at 22-241C with ambient humidity levels) with ad libitum access to food and water, unless otherwise noted.
Acute food intake in mice and rats The acute effect of exenatide on food intake was investigated in standard chow-fed mice and rats. In the first set of experiments, subjects were group-housed, overnight-fasted (16 In a second experiment, the peripheral versus central actions of exenatide were compared during natural feeding. Male Sprague-Dawley rats (250-300 g) were surgically implanted with intracerebroventricular (i.c.v.) cannula in the lateral ventricle at Zivic Laboratories (Pittsburgh, PA, USA; from bregma: AP À0.8 mm, ML þ 1.5 mm, DV À4.8 mm). Rats were shipped to Amylin, individually housed, and habituated to the facility and diet for 4 weeks (standard chow diet LM-485 Teklad, Madison, WI, USA). On the test day (weight ¼ 42575 g), food was removed at 1500 hours. At 1700 hours, immediately before the onset of the dark cycle, animals received an i.c.v. injection (2 ml) of vehicle (0.9% saline) or exenatide (0.024-24 mg/kg) and food was made available. Following a 3-week washout period, the same rats were randomly divided into treatment groups and tested under identical conditions with an i.p. injection (100 ml) of vehicle or exenatide (0.024-240 mg/kg). Food intake following both i.c.v. and i.p. administration was measured 2 h postinjection. Verification of cannula placement was made via histological analysis at the end of the study.
Sustained exposure in high-fat-fed mice and rats Subjects were group-housed 4-week-old male C57BL/6J mice (14 g; Jackson Laboratory, Bar Harbor, ME, USA) maintained on an HF diet (58% fat kcal; D12331, Research Diets, New Brunswick, NJ, USA) for 28 days. The C57BL/6J mouse strain is prone to weight gain under HF dietary conditions. 38 At the end of the fattening period, mice were divided into groups of equal body weight (mean7s.e.m. at time of implant ¼ 26.571.4 g). Under isoflurane anesthesia, animals were implanted subcutaneously with 28-day osmotic pumps (#2004, Durect Corp., Cupertino, CA, USA) delivering vehicle (50% dimethylsulfoxide (DMSO) in water) or exenatide (3-30 mg/kg/day, flow rate ¼ 0.25 ml/h). Mice remained on the HF diet for the duration of the study. Food intake and body weight were measured weekly. At 28 days, Exenatide reduces body weight in high-fat-fed rats CM Mack et al overnight-fasted mice (16 h) were killed by cardiac puncture under isoflurane anesthesia. Approximately 800 ml of blood was collected in eppendorf tubes coated with ethylenediaminetetraacetic acid (EDTA). The blood was centrifuged (1 min, 10 000 r.p.m.), and plasma then frozen in dry ice and stored (À701C). Plasma triglycerides and total cholesterol were determined by standard enzymatic methods adapted for the COBAS Mira plasma analyzer (Roche Diagnostics, Indianapolis, IN, USA). Plasma insulin was measured with an ultrasensitive mouse insulin enzyme-linked immunosorbent assay as per the manufacturer's instructions (catalog number: 08-10-1150-01, ALPCO Diagnostics, Salem, NH, USA). Carcasses were frozen with liquid nitrogen, and fat and protein contents were determined by Soxhlet extraction 39 and Dumas method, 40 respectively (Covance Laboratories,
Madison, WI, USA). In a second experiment, individually housed male Sprague-Dawley rats (340 g; Harlan, San Diego, CA, USA) were maintained on the HF diet described above for 28 days. At the end of the fattening period, rats were divided into groups of equal body weight (mean7s.e.m. at time of implant ¼ 45474 g). Under isoflurane anesthesia, animals were implanted subcutaneously with 28-day osmotic pumps (#2ML4, Durect Corp.) delivering vehicle (50% DMSO in water) or exenatide (3-30 mg/kg/day, flow rate ¼ 2.5 ml/h). Rats remained on the HF diet for the duration of the study. Food intake and body weight were measured weekly. At 28 days, rats were killed by cardiac puncture under isoflurane anesthesia. Approximately 8 ml of blood was collected in eppendorf tubes coated with EDTA. The blood was centrifuged (5 min, 10 000 r.p.m.), and plasma then frozen in dry ice and stored (À701C). Plasma exenatide concentrations were determined as described previously. 39 
Kaolin consumption
Individually housed male Sprague-Dawley rats (300 g) consuming a standard laboratory diet (LM-485 Teklad, Madison, WI, USA) were introduced to kaolin pellets (#K5001, Research Diets, New Brunswick, NJ, USA), similar in shape and size to their chow, for 3 days before experimentation. On day 4, rats were assigned to treatment groups balanced for chow and kaolin intake. Animals were fasted overnight (16 h, both chow and kaolin removed) on day 5. The following morning, rats were injected i.p. (1 ml/kg) with vehicle (10% DMSO in water), cisplatin (3 mg/kg) or exenatide (0.10, 1 or 10 mg/kg). Immediately after the injection, rats were returned to their respective cages containing a measured quantity of chow and kaolin. Kaolin and chow intakes were determined 24 h following the injection. Statistical analysis Group differences were assessed using analysis of variance followed by Dunnett's post hoc comparisons (Systat version 10.2). Nonlinear regression (sigmoidal dose-response) was used to examine dose-response and concentration-response relationships. Percent body weight loss (vehicle-corrected) was calculated as follows: (mean vehicle body weight gainpeptide body weight gain/initial body weight) Â 100. The significance level was set at Po0.05. All data are presented as mean7s.e.m.
Locomotor activity
Results
Acute effects on food intake in mice and rats At 60 min post-injection, i.p. administered exenatide produced a dose-dependent suppression of food intake in fasted mice (Figure 1a) . The half-maximal effective dose (ED 50 ) for food intake suppression was 2.3 mg/kg70.11 log units, with a maximal suppression of 70%. Similar ED 50 values were observed at the 30 and 120 min time points (1.2 and 2.5 mg/ kg, respectively, data not shown). At 2.4 mg/kg (approximate ED 50 ), exenatide significantly decreased cumulative food intake compared to vehicle at the 120, 180, 240 and 300 min time points (Figure 1b) .
Similarly, both i.p. and i.c.v. administration of exenatide to rats at the onset of the dark cycle dose-dependently reduced food intake at 2 h post-injection (Figure 2 ). At the doses tested, the ED 50 following i.p. administration was 46.3 mg/kg70.41 log units, with a maximal suppression of food intake of 75%. The ED 50 following i.c.v. injection was 0.37 mg/kg70.17 log units; at the higher doses tested, food intake was virtually abolished (94% suppression).
Effect of sustained exposure on food intake, body weight, metabolic indicators and body composition in high-fat-fed mice Sustained peripheral exposure of HF-fed mice to exenatide for 28 days dose-dependently suppressed body weight gain throughout the treatment period (Figure 3a) . Compared to vehicle, body weight gain was significantly reduced at the 10 and 30 mg/kg/day doses at all time points. At 28 days, percent body weight loss was 2.170.7, 9.470.9 and 16.470.9% at 3, 10 and 30 mg/kg/day, respectively (ED 50 ¼ 19 mg/kg/day7 0.2 log units). Concomitant changes in food intake were Exenatide reduces body weight in high-fat-fed rats CM Mack et al observed: compared to vehicle, food intake was significantly reduced at 10 and 30 mg/kg/day of exenatide for the first 3 weeks of treatment (Figure 3b ). This effect remained statistically significant during week 4 in mice treated with 30 mg/kg/day of exenatide. When food intake was expressed per kg of body weight, there were no instances of increased food intake in exenatide-treated mice compared to controls (all P40.05, data not shown). Plasma analysis at termination (Figure 4 ) revealed significant decreases in exenatide versus control rats in total cholesterol and triglyceride levels at the highest dose tested. Plasma insulin was significantly decreased at both 10 and 30 mg/kg/day. Body composition analysis showed a significant reduction in body fat content at 10 and 30 mg/kg/day of exenatide compared to vehicle ( Figure 5 ); no differences between groups were found in protein content.
Effect of sustained exposure on food intake and body weight in high-fat-fed rats Similar to its effects in HF-fed mice, exenatide dosedependently decreased body weight gain throughout the treatment period in HF-fed rats (Figure 6a ). Compared to vehicle, body weight gain was significantly reduced at all doses throughout the study, with the exception of the 3 mg/ kg/day dose on day 28. (Figure 7 ). Exenatide reduces body weight in high-fat-fed rats CM Mack et al
Effects on kaolin consumption and locomotor activity in rats
At 24 h post-injection, cisplatin significantly decreased food intake and increased kaolin intake (Po0.05), whereas, exenatide at 10 mg/kg significantly reduced food intake (Po0.05) but failed to induce kaolin intake (Figure 8a and b). Dose-dependent changes were found in locomotor activity in rats treated with exenatide. Distance traveled was decreased and rest time increased compared to controls, with significant effects first apparent at a dose of 0.50 mg/kg (Figure 9a and b) . Under identical conditions, decreased food intake was first discernable at 0.25 mg/kg (Figure 9c ).
Discussion
The current results confirm the ability of exenatide to dosedependently reduce acute food intake in rodents. Furthermore, we show for the first time that continuous peripheral exposure for 28 days to normal (those with an intact leptin signaling system) HF-fed mice and rats dose-dependently decreased food intake and body weight gain. These effects were associated with a decrease in fat mass in the presence of sparing of lean tissue, and an improved metabolic profile. Exenatide reduces body weight in high-fat-fed rats CM Mack et al
In the presence of decreased food intake, exenatide had no effect on kaolin consumption, a preclinical marker of emesis. The dose-response relationships for locomotor activity and food intake were highly correlated with exenatide treatment, although a higher dose was required to produce statistically significant changes in activity than to reduce food intake. Acutely, peripherally administered exenatide potently inhibited 60 min food intake in fasted mice with an ED 50 of B2 mg/kg, consistent with previous reports. 31 In rats, the potency of exenatide to reduce food intake following i.p. or i.c.v. administration is also within the range of those reported previously. 25, 27 Consistent with a plasma half-life of 150 min in rats (i.p.), 5 the effect of exenatide, at the ED 50 dose, was sustained for 5 h post-injection. Although dose dependent, this effect has shown to be durable in normal mice for 24 h. 31 Sustained exenatide exposure produced a persistent reduction in body weight in both mice and rats, with a maximal weight loss at 4 weeks of 16 and 11%, respectively. The demonstrated action of peripheral exenatide to reduce weight in monogenic models of obesity 6, 18, 27, 28 can now be Exenatide reduces body weight in high-fat-fed rats CM Mack et al extended to normal rats consuming an HF diet. Comparing our findings with those from leptin-receptor-deficient models, both ZDF 6 and fa/fa rats 18, 27, 28 show weight reductions of similar magnitude, suggesting that exenatide effects are mediated via a leptin-independent pathway. Exenatide displayed greater efficacy in mice than rats, as evidenced by greater weight loss and persistence of reduced food intake throughout the study. Consistent with a state of negative balance, exenatide acutely reduces metabolic rate in rodents. 45 The long-term effects of systemic exenatide on energy expenditure have not been examined. Pair-fed fa/fa rats show equivalent weight reductions as those treated for 6 weeks with exenatide, 18 suggesting that a major part of exenatide's actions can be attributed to a reduction in food intake. Similarly, food intake is reduced in humans following exenatide 46 or GLP-1 47 infusion. We also found that weight loss was accompanied by a loss of fat tissue, with a sparing of lean mass. This is the first report showing a sparing of lean mass with exenatide treatment in the presence of decreased body weight and concomitant decreased fat mass. Exenatide also reduced total cholesterol and triglycerides in mice; insulin concentrations were also reduced, potentially reflecting an improvement in insulin sensitivity, consistent with observations in other studies. 6, 18 Consistent with the improved metabolic profile observed in mice, patients with type 2 diabetes show improvements in cardiovascular risk factors with exenatide treatment, including decreased triglycerides. 48 Potential nonhomeostatic reductions in food intake with exenatide were evaluated in the kaolin consumption and locomotor activity models. Exenatide did not elicit kaolin consumption in the presence of decreased food intake. As a positive control, cisplatin, a chemotherapeutic agent that elicits emesis in humans, decreased food intake and increased kaolin consumption. Reversal of lithium chlorideinduced kaolin ingestion has been observed following i.c.v. administration of a GLP-1 antagonist, 34 but this effect may reflect stimulation of a different population of GLP-1 receptors that are not activated following systemic exposure. Both food intake and locomotor activity were dosedependently reduced with acute exenatide treatment in rats, but were dissociable within a narrow dose range. This dissociation has also been demonstrated in mice, as 0.06 mg (B2.4 mg/kg) of i.p. administered exenatide reduced food intake but had no effect on locomotor activity, or on CTA, a model of visceral illness; 31 a higher dose of 3 mg (120 mg/kg) decreased both food intake and locomotor activity, and induced CTA. It is feasible that additional GLP-1 receptor populations are recruited at the higher doses, resulting in decreased locomotion. Although demonstrating dissociation of food intake and side-effect measures by comparing doseresponse relationships suggests activation of energy pathways, it remains possible that subthreshold doses may still produce aversive consequences without signs of overt illness. The biology underling exenatide's effect on activity, and its contribution to reducing food intake, is unclear. In the clinic, a small percentage of exenatide-treated patients (placebo-corrected) experience emesis (9%), consistent with our current findings in the kaolin model in rats, whereas a greater proportion report nausea (38%). 10 Both events are mild to moderate in nature, and decrease with continued treatment. The finding that weight loss in exenatide-treated patients (10 mg, twice daily) continues for at least 82 weeks in the absence of continued nausea 42 points to a satiety-related mechanism of exenatide contributing to reduction of body Exenatide reduces body weight in high-fat-fed rats CM Mack et al weight, and not through pathways mediating aversive states. It should be noted that central activation of GLP-1 pathways in rodents through the i.c.v. route of administration is also associated with CTA. 21, [32] [33] [34] However, site-specific administration of GLP-1 in the CNS shows this effect to be mediated by distinct GLP-1 receptor populations that are separable from those mediating food intake effects. 49, 50 In summary, the current data demonstrate for the first time the ability of peripherally administered exenatide to reduce body weight gain and improve metabolic profile in normal rodents consuming an HF diet, a model that parallels the genetic variability and environmental conditions contributing to human obesity, and supports a role for exenatide in metabolic pathways mediating food intake and body weight.
